Cantargia: Development of new antibody-based cancer treatments

Episode Loading...

PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: Cantargia: Development of new antibody-based cancer treatments
Released on: January 05, 2017. © PharmaVentures Ltd
Share/save this page:
Follow us:
In This Episode:
    Cantargia specialises in antibody-based cancer treatment.
  • Summary
  • Participants
  • Company
Cantargia specialises in antibody-based cancer treatment. CAN04, the company's patented antibody treatment, has a dual mechanism of action. CAN04 fights cancer by activating the immune system and blocking signals that lead to tumour growth. Treatment with CAN04 has the potential to become an important part of modern immuno-oncology.
Göran Forsberg has a PhD in biochemistry, and is an associate professor and the author of over 40 scientific publications. He has worked for pharmaceutical and biotechnology companies for more than 25 years in various positions, including at KabiGen, Pharmacia, Active Biotech and the University of Adelaide, Australia. Forsberg’s most recent position was Chief Business Officer at Active Biotech AB. He has a large amount of drug development experience, with a special focus on oncology.Since 2011, Forsberg is a board member of Isogenica Ltd.
Many diseases are very complex and, despite considerable research, new treatments are still very much needed. One of these diseases is cancer. Despite major progress being made, cancer is still one of the major causes of death and a disease with which great suffering is associated. That's why we at Cantargia see our job as important, challenging and a way of contributing to more effective and gentle cancer treatments in the future. The knowledge we have acquired within our cancer-related research has also provided us with information that we can utilise to develop products for other serious diseases, such as autoimmune and inflammatory diseases. Vision Cantargia's vision is to develop and safeguard a novel generation of drugs targeting IL1RAP, making the cancer treatments of tomorrow more effective. This vision also includes the development of new product candidates to treat autoimmune/inflammatory diseases. Scientific strategy Cantargia works virtually through a multitude of collaborations with different contractors, companies, hospitals and academic groups to deliver the CAN04 project. Between 20 and 30 local or international parties are currently working on CAN04 research and development. Cantargia's strategy is to assume overall responsibility for the development of its product candidates until there is an indication of clinical activity. The aim is to be in a position for a partner to take on and continue the development of the project in a time-efficient manner and in doing so avoid delaying a launch.